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creativecommons.org/licenses/by-nc-nd/Abstract Overdiagnosis in breast cancer screening is an important issue. A recent study from
Denmark concluded that one in three breast cancers diagnosed in screening areas in women
aged 50e69 years were overdiagnosed. The purpose of this short communication was to disen-
tangle the study’s methodology in order to evaluate the soundness of this conclusion. We
found that both the use of absolute differences as opposed to ratios; the sole focus on non-
advanced tumours and the crude allocation of tumours and person-years by screening history
for women aged 70e84 years, all contributed to the very high estimate of overdiagnosis.
Screening affects cohorts of screened women. Danish registers allow very accurate mapping
of the fate of every woman. We should be past the phase where studies of overdiagnosis
are based on the fixed age groups from routine statistics.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
When it comes to evaluation of breast cancer screening,
Denmark is in a particular position. A population-basedk (E. Lynge).
18
blished by Elsevier Ltd. This is
4.0/).screening program was offered to around 20% of Danish
women up to 17 years before it was offered to the rest of
Danish women. This allows for comparison of women
exposed and women not exposed to screening. Thean open access article under the CC BY-NC-ND license (http://
E. Lynge et al. / European Journal of Cancer 80 (2017) 26e29 27screening program targeted women aged 50e69 years,
and opportunistic screening was rare. On this basis,
several studies have been undertaken on the impact of
screening on breast cancer mortality [1e3], and over-
diagnosis [4e6].
Recently, Jørgensen et al. [7] published a new Danish
study on overdiagnosis. This study was based on the
number of breast cancers divided into advanced
(>20 mm in tumour diameter) and non-advanced cases.
Person-years were estimated from the official Danish
statistics. Incidence rates were calculated for women
aged 35e49, 50e69 and 70e84 years and for two
geographical areas (screening and non-screening area)
and two periods (before and after screening started).
The study concluded that ‘one in every three women
aged 50e69 years diagnosed with breast cancer was
overdiagnosed in the screening area’.
If true, breast cancer screening in Denmark causes
considerable harm and would be unjustified as a public
health policy. It is therefore important to understand the
analysis behind the conclusion by Jørgensen et al. With
this purpose in mind, we looked into the details of the
methodology. Jørgensen et al. estimated overdiagnosis
in breast cancer screening in Denmark using two ap-
proaches, and we discussed them one by one.Table 1
Incidence rates of breast cancer per 100,000 person-years among
women aged 50e84 years and changes over time calculated as a dif-
ference and as a ratio (data from Jørgensen, Table 3).
Area Before After Difference Ratio
Screening 226.1 351.3 125.2 1.55







(i.e. [27.6/280]  100)
1%
a The estimate of overdiagnosis by Jørgensen et al.2. Jørgensen approach 1
First, overdiagnosis was calculated based on absolute
difference in changes of breast cancer incidence rates:
(absolute difference between after and before in
screening area)e(absolute difference between after and
before in non-screening area) as numerator, and the
incidence rate in the after period in the non-screening
area as denominator. For women aged 50e84 years, this
gave ([351.3e226.1]e[280e182.4])/280 Z 0.099 or 9.9%
(Jørgensen Table 3). All incidence rates were per
100,000, but for simplicity, we omitted the ‘per 100,000’
from both numerator and denominator.
However, the absolute difference in an outcome be-
tween an exposed and a non-exposed group cannot be
used as a measure of the strength of the association
between the exposure and the outcome. The size of the
absolute difference depends not only on the changes
over time but also on the levels before. Let us illustrate
this with an example. In the data by Jørgensen et al.,
(Jørgensen Table 3) for women aged 50e84 years, the
incidence rate before screening was 226.1 in the
screening area and 182.4 in the non-screening area. If
both incidence rates increased by 10% they would
become 248.7 and 200.6, respectively. The two areas had
then undergone exactly the same changes over time, and
the ratio of the rate ratios would be 1.00, but the ab-
solute difference would be 4.4.
The actual impact of screening on breast cancer
incidence would therefore be better measured with theratio of rate ratios than with the absolute difference
(Table 1). In the data by Jørgensen et al., the ratio of the
rate ratios was 1.01 (i.e. [351.3/226.1]/[280/182.4]) (Jør-
gensen Table 3). This would indicate an overdiagnosis of
1%, as compared with the overdiagnosis of 9.9%, Jør-
gensen et al. calculated from the absolute difference.
Both calculations are, however, problematic due to
limitations in the study design used by Jørgensen et al.,
see in the following section.
3. Jørgensen approach 2
Second, overdiagnosis was calculated from the increase
in non-advanced tumours in women aged 50e69 years.
Advanced tumours were disregarded in the calculation
for two reasons. The first reason was because the rate
‘did not decrease in the screening area when incidence
trends among women aged 35e49 years were accounted
for’. For advanced tumours, the ratios of the rate ratios
were 0.48, 0.66 and 0.69, respectively, for women aged
35e49, 50e69 and 70e84 years (Jørgensen Table 2). So,
there was a decrease in all age groups, but the authors’
argument seems to be that given a decrease in the rate in
women below screening age, screening could not explain
the decrease in the rate in women above screening age.
The change in women below screening age is of course
interesting but hardly tells about impact of screening.
The second reason for disregarding advanced tu-
mours was because ‘there was no compensatory decrease
in the incidence of advanced tumours in older women’.
Older women are here women aged 70e84 years.
However, in older women, the ratio of the rate ratios for
advanced tumours did in fact decrease more in screening
than in non-screening areas; (154.8/124.0)/(162.2/
89.7) Z 0.69 (Jørgensen Table 2; 95% confidence inter-
val 0.63e0.75, our calculation). It therefore seems
strange that the authors found that overdiagnosis could
be estimated based solely on data for non-advanced
tumours.
In the second approach, the numerator was the ab-
solute difference in changes of incidence rates in non-
advanced breast cancer and the denominator was the
incidence rate of advanced and non-advanced breast
cancer in the non-screening area. For women aged
E. Lynge et al. / European Journal of Cancer 80 (2017) 26e292850e69 years, this gave ([258.9e111.4]e[142.0e95.6])/
262.1 Z 0.386, or 38.6% (Jørgensen Table 2). The au-
thors added an absolute difference in incidence of ductal
carcinoma in situ (DCIS) between screening and non-
screening areas in the after period. This was
(38.2e12.4) Z 25.8. Together (101.1 þ 25.8)/
262.1Z 0.483, or 48.3%; resulting in the conclusion that
‘1 in every 3 women aged 50e69 years diagnosed with
breast cancer was overdiagnosed’. Estimates of over-
diagnosis are highly depending on not only the numer-
ator but also on the denominator [8]. For women aged
50e84 years, Jørgensen estimated an overdiagnosis of
26% (Jørgensen Table 4), not including DCIS.
In the studied screening areas, screen-detected tu-
mours constituted 54% of all tumours (screen-detected,
interval cancers and tumours in non-participants) when
DCIS was included and 51% when only invasive tu-
mours were included [9]. Overdiagnosis can affect only
the screen-detected part of the tumours. With the
calculation by Jørgensen et al., about half of the tu-
mours detected at screening should be overdiagnosed
(i.e. [1.486e0.46]/0.54 Z x; x Z 1.89).4. Jørgensen study design
A key problem with the study by Jørgensen et al. was the
design. Screening changes the age-specific pattern of
breast cancer incidence in the targeted birth cohorts [10],
including a prevalence peak during the first screen, an
artificial ageing during the subsequent screens and a
compensatory decrease after the end of screening age
[11].Fig. 1. Lexis’ diagram. Women aged 70e84 years in the municipalityIn Denmark, screening targeting women aged
50e69 years at the beginning of a biennial invitation
round started in Copenhagen in April 1991; screening
targeting women aged 50e69 years at the time of invi-
tation started in Funen in November 1993 and screening
targeting women aged 50e69 years started in Freder-
iksberg in June 1994 (program later merged with that of
Copenhagen). During the first biennial rounds also
women above the age of 70 years were invited.
For women ‘no longer offered screening’, Jørgensen
et al. used data from the age group of 70e84 years for
the period of 1991e2010 from Copenhagen and Fred-
eriksberg and from 1994 to 2010 for Funen. For
Copenhagen, these observations are illustrated in Fig. 1.
However, some women contributing observations were
never invited to screening (in red), and a small part of
the women were still invited despite having passed the
age of 70 years (in blue). Furthermore, women over
screening age still develop new incident cancers unaf-
fected by screening (in grey and green). In Denmark, the
compensatory decrease occurred mainly within the first
8 years after women were no longer invited (in grey) [6].
Jørgensen et al. had 3530 invasive breast cancers in
the age group of 70e84 years in the screening area in the
after period (Jørgensen Supplementary Table). Data
were not provided by screening program and detailed
age group. However, Copenhagen constituted about
40% of the targeted population; Frederiksberg 10% and
Funen 50%. Jørgensen et al. used breast cancer data for
20 years from Copenhagen and Frederiksberg and from
17 years from Funen. For the illustration here, it was
therefore reasonable to assume that 1526 of the cancers
came from Copenhagen; 382 from Frederiksberg andof Copenhagen, Denmark, 1991e2010 by screening experience.
Table 2
Estimated distribution of 3530 invasive breast cancers by screening status for women aged 70e84 years in screening areas 1991/1994e2010 in the
Jørgensen data.
Screening status Copenhagen Frederiksberg Funen Total breast cancer
% observationsa N breast cancer % observationsa N breast cancer % observationsa N breast cancer N %
Never invited 37.5% 572 52.5% 201 44.1% 715 1488 42.1%
Still invited 6.0% 92 2.7% 10 6.3% 102 204 5.8%
Post invitation
<8 years
42.0% 641 34.0% 130 40.8% 662 1433 40.6%
Post invitation
8 years
14.5% 221 10.8% 41 8.8% 143 405 11.5%
Total 100% 1526 100% 382 100% 1622 3530 100%
a Percent of area in Lexis’ diagram.
E. Lynge et al. / European Journal of Cancer 80 (2017) 26e29 291622 from Funen. A rough estimation indicated that
42% of the breast cancers in the age group of 70e84
years occurred in women never offered screening, 6% in
women still invited to screening, 41% in women who
stopped being invited for screening within the last 8
years and 11% in women who stopped being invited for
screening more than 8 years ago (Table 2). It is not
possible to capture correctly the size of overdiagnosis
with such crude data.5. Conclusion
Our analysis illustrated that several factors contributed
to the very high estimate of overdiagnosis presented by
Jørgensen et al. [7]. First, the use of absolute differences
as opposed to ratios; second, focus on only non-
advanced cancers and third, an inadequate study
design. Screening affects the age-specific incidence of
breast cancer in cohorts of screened women, but this
classic wisdom has not yet entered mainstream epide-
miology. Studies of overdiagnosis are still published
without proper consideration of the cohort perspective,
and the study by Jørgensen et al. is an example. For the
sake of screened women, researchers and journal editors
should join efforts to find the best possible method for
estimation of overdiagnosis.Funding
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